Transplantation in the treatment of age-related macular degeneration: Past, present and future directions

Expert Review of Ophthalmology

Volumn 2, Issue 3, 2007, Pages 497-511

  Sheridan, Carl ^a   Krishna, Yamini ^a   Williams, Rachel ^a   Mason, Sharon ^a   Wong, David ^a   Heimann, Heinrich ^b   Kent, David ^c   Grierson, Ian ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b University Hospital   (United Kingdom)

^c Aut Even Hospital   (United Kingdom)

Author keywords

age related macular degeneration; artificial substrate; iris pigment epithelial cell; patch graft; retinal pigment epithelial cell; stem cell; transplant

Indexed keywords

EID: 79954985980     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.3.497     Document Type: Article

References (105)

1. Tasman W, Rovner B. Age-related macular degeneration: treating the whole patient. Arch. Ophthalmol. 122, 648–649 (2004).
2. Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. Br. Med. J. 326, 485–488 (2003).
3. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR. Age-related macular degeneration: economic burden and value-based medicine analysis. Can. J. Ophthalmol. 40, 277–287 (2005).
4. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol. 48, 257–293 (2003).
5. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 134, 411–431 (2002).
6. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 45, 115–134 (2000).
7. Klein R, Klein BE, Tomany SC, Moss SE. Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study. Am. J. Epidemiol. 156, 589–598 (2002).
8. Goverdhan S, Lotery AJ. New insights into the molecular genetics of age-related macular degeneration. Eyenews 12, 9–12 (2005).
9. Gold B, Merriam JE, Zernant J et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 38, 458–462 (2006).
10. Scholl HP, Fleckenstein M, Issa PC, Keilhauer C, Holz FG, Weber BH. An update on the genetics of age-related macular degeneration. Mol. Vis. 13, 196–205 (2007).
11. Schultz DW, Weleber RG, Lawrence G et al. Hemicentin-1 (fibulin-6) and the 1q31 AMD locus in the context of complex disease: review and perspective. Ophthalmic Genet. 26, 101–105 (2005).
12. Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385–389 (2005).
13. Zareparsi S, Buraczynska M, Branham KE et al. Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration. Hum. Mol. Genet. 14, 1449–1455 (2005).
14. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch. Ophthalmol. 122, 598–614 (2004).
15. Smith W, Assink J, Klein R et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 108, 697–704 (2001).
16. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in drusen formation. Exp. Eye Res. 70, 441–449 (2000).
17. Forrester JV, Dick AD, McMenamin PG, Lee WR. The eye: basic sciences in practice. WB Saunders, London, UK (2002).
18. Kent D, Sheridan C. Choroidal neovascularization: a wound healing perspective. Mol. Vis. 9, 747–755 (2003).
19. Schwesinger C, Yee C, Rohan RM et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am. J. Pathol. 158, 1161–1172 (2001).
20. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE–Bruch’s membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 20, 705–732 (2001).
21. Bird AC, Bressler NM, Bressler SB et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv. Ophthalmol. 39, 367–374 (1995).
22. Bylsma GW, Guymer RH. Treatment of age-related macular degeneration. Clin. Exp. Optom. 88, 322–334 (2005).
23. Grossniklaus HE, Miskala PH, Green WR et al. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: Submacular Surgery Trials Report no. 7. Arch. Ophthalmol. 123, 914–921 (2005).
24. Lafaut BA, Bartz-Schmidt KU, Vanden BC, Aisenbrey S, De Laey JJ, Heimann K. Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br. J. Ophthalmol. 84, 239–243 (2000).
25. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case–control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 107, 2224–2232 (2000).
26. Chaine G, Hullo A, Sahel J et al. Case–control study of the risk factors for age related macular degeneration. France-DMLA Study Group. Br. J. Ophthalmol. 82, 996–1002 (1998).
27. Brunner R, Widder RA, Walter P et al. Influence of membrane differential filtration on the natural course of age-related macular degeneration: a randomized trial. Retina 20, 483–491 (2000).
28. Silva JN, Filipe P, Morliere P et al. Photodynamic therapies: principles and present medical applications. Biomed. Mater. Eng. 16, S147 –S154 (2006).
29. Zhou B, Wang B. Pegaptanib for the treatment of age-related macular degeneration. Exp. Eye Res. 83, 615–619 (2006).
30. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26, 859–870 (2006).
31. Augustin AJ, Offermann I. Emerging drugs for age-related macular degeneration. Expert. Opin. Emerg. Drugs 11, 725–740 (2006).
32. Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 26, 602–612 (2006).
33. Slakter JS. Anecortave acetate for treating or preventing choroidal neovascularization. Ophthalmol. Clin. North Am. 19, 373–380 (2006).
34. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog. Retin. Eye Res. 20, 385–414 (2001).
35. Bressler NM, Bressler SB, Childs AL et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology 111, 1993–2006 (2004).
36. Lai JC, Lapolice DJ, Stinnett SS et al. Visual outcomes following macular translocation with 360-degree peripheral retinectomy. Arch. Ophthalmol. 120, 1317–1324 (2002).
37. Wong D, Stanga P, Briggs M et al. Case selection in macular relocation surgery for age related macular degeneration. Br. J. Ophthalmol. 88, 186–190 (2004).
38. Cahill MT, Freedman SF, Toth CA. Macular translocation with 360 degrees peripheral retinectomy for geographic atrophy. Arch. Ophthalmol. 121, 132–133 (2003).
39. van Meurs JC, Van Den Biesen PR. Autologous retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration: short-term follow-up. Am. J. Ophthalmol. 136, 688–695 (2003).
40. Stanga PE, Kychenthal A, Fitzke FW et al. Retinal pigment epithelium translocation after choroidal neovascular membrane removal in age-related macular degeneration. Ophthalmology 109, 1492–1498 (2002).
41. MacLaren RE, Bird AC, Sathia PJ, Aylward GW. Long-term results of submacular surgery combined with macular translocation of the retinal pigment epithelium in neovascular age-related macular degeneration. Ophthalmology 112, 2081–2087 (2005).
42. MacLaren RE, Uppal GS, Balaggan KS et al. Autologous transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degeneration. Ophthalmology 114, 561–570 (2007).
43. Joussen AM. How complete is successful? ‘Autologous retinal pigment epithelium and choriod translocation in patients with exsudative age-related macular degeneration: a short-term follow-up’ by Jan van Meurs and P.R. van Biesen. Graefes Arch. Clin. Exp. Ophthalmol. 241, 966–967 (2003).
44. Joussen AM, Heussen FM, Joeres S et al. Autologous translocation of the choroid and retinal pigment epithelium in age-related macular degeneration. Am. J. Ophthalmol. 142, 17–30 (2006).
45. Joussen AM, Joeres S, Fawzy N et al. Autologous translocation of the choroid and retinal pigment epithelium in patients with geographic atrophy. Ophthalmology 114, 551–560 (2007).
46. Aramant RB, Seiler MJ. Progress in retinal sheet transplantation. Prog. Retin. Eye Res. 23, 475–494 (2004).
47. Del Priore LV, Ishida O, Johnson EW et al. Triple immune suppression increases short-term survival of porcine fetal retinal pigment epithelium xenografts. Invest. Ophthalmol. Vis. Sci. 44, 4044–4053 (2003).
48. Sauve Y, Girman SV, Wang S, Keegan DJ, Lund RD. Preservation of visual responsiveness in the superior colliculus of RCS rats after retinal pigment epithelium cell transplantation. Neuroscience 114, 389–401 (2002).
49. Algvere PV, Gouras P, Dafgard KE. Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD. Eur. J. Ophthalmol. 9, 217–230 (1999).
50. del Cerro CM, Humayun MS, Sadda SR et al. Histologic correlation of human neural retinal transplantation. Invest. Ophthalmol. Vis. Sci. 41, 3142–3148 (2000).
51. Radtke ND, Aramant RB, Seiler MJ, Petry HM, Pidwell D. Vision change after sheet transplant of fetal retina with retinal pigment epithelium to a patient with retinitis pigmentosa. Arch. Ophthalmol. 122, 1159–1165 (2004).
52. Yamamoto S, Du J, Gouras P, Kjeldbye H. Retinal pigment epithelial transplants and retinal function in RCS rats. Invest. Ophthalmol. Vis. Sci. 34, 3068–3075 (1993).
53. Coffey PJ, Girman S, Wang SM et al. Long-term preservation of cortically dependent visual function in RCS rats by transplantation. Nat. Neurosci. 5, 53–56 (2002).
54. Lund RD, Adamson P, Sauve Y et al. Subretinal transplantation of genetically modified human cell lines attenuates loss of visual function in dystrophic rats. Proc. Natl Acad. Sci. USA 98, 9942–9947 (2001).
55. Phillips SJ, Sadda SR, Tso MO, Humayan MS, de Juan E Jr, Binder S. Autologous transplantation of retinal pigment epithelium after mechanical debridement of Bruch’s membrane. Curr. Eye Res. 26, 81–88 (2003).
56. Grisanti S, Szurman P, Jordan J, Kociok N, Bartz-Schmidt KU, Heimann K. Xenotransplantation of retinal pigment epithelial cells into RCS rats. Jpn J. Ophthalmol. 46, 36–44 (2002).
57. Knoernschild T, Grasbon T, Wilsch C, Kampik A, Lutjen-Drecoll E. RPE cell transplants to non-immune-privileged sites of the eye transform into fibroblast-like cells. Curr. Eye Res. 27, 25–34 (2003).
58. Binder S, Krebs I, Hilgers RD et al. Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: a prospective trial. Invest. Ophthalmol. Vis. Sci. 45, 4151–4160 (2004).
59. van Meurs JC, ter Averst E, Hofland LJ et al. Autologous peripheral retinal pigment epithelium translocation in patients with subfoveal neovascular membranes. Br. J. Ophthalmol. 88, 110–113 (2004).
60. Kanuga N, Winton HL, Beauchene L et al. Characterization of genetically modified human retinal pigment epithelial cells developed for in vitro and transplantation studies. Invest. Ophthalmol. Vis. Sci. 43, 546–555 (2002).
61. Thumann G. Development and cellular functions of the iris pigment epithelium. Surv. Ophthalmol. 45, 345–354 (2001).
62. Cai H, Shin MC, Tezel TH, Kaplan HJ, Del Priore LV. Use of iris pigment epithelium to replace retinal pigment epithelium in age-related macular degeneration: a gene expression analysis. Arch. Ophthalmol. 124, 1276–1285 (2006).
63. Lappas A, Foerster AM, Weinberger AW, Coburger S, Schrage NF, Kirchhof B. Translocation of iris pigment epithelium in patients with exudative age-related macular degeneration: long-term results. Graefes Arch. Clin. Exp. Ophthalmol. 242, 638–647 (2004).
64. Abe T, Yoshida M, Tomita H et al. Auto iris pigment epithelial cell transplantation in patients with age-related macular degeneration: short-term results. Tohoku J. Exp. Med. 191, 7–20 (2000).
65. Crafoord S, Geng L, Seregard S, Algvere PV. Photoreceptor survival in transplantation of autologous iris pigment epithelial cells to the subretinal space. Acta Ophthalmol. Scand. 80, 387–394 (2002).
66. Semkova I, Kreppel F, Welsandt G et al. Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye. Proc. Natl Acad. Sci. USA 99, 13090–13095 (2002).
67. Lappas A, Weinberger AW, Foerster AM, Kube T, Rezai KA, Kirchhof B. Iris pigment epithelial cell translocation in exudative age-related macular degeneration. A pilot study in patients. Graefes Arch. Clin. Exp. Ophthalmol. 238, 631–641 (2000).
68. Thumann G, Aisenbrey S, Schraermeyer U et al. Transplantation of autologous iris pigment epithelium after removal of choroidal neovascular membranes. Arch. Ophthalmol. 118, 1350–1355 (2000).
69. Aisenbrey S, Lafaut BA, Szurman P et al. Iris pigment epithelial translocation in the treatment of exudative macular degeneration: a 3-year follow-up. Arch. Ophthalmol. 124, 183–188 (2006).
70. Laurent G. Directed issue on stem cells. Int. J. Biochem. Cell Biol. 36, 553 (2004).
71. Enzmann V, Howard RM, Yamauchi Y, Whittemore SR, Kaplan HJ. Enhanced induction of RPE lineage markers in pluripotent neural stem cells engrafted into the adult rat subretinal space. Invest. Ophthalmol. Vis. Sci. 44, 5417–5422 (2003).
72. Young MJ, Ray J, Whiteley SJ, Klassen H, Gage FH. Neuronal differentiation and morphological integration of hippocampal progenitor cells transplanted to the retina of immature and mature dystrophic rats. Mol. Cell Neurosci. 16, 197–205 (2000).
73. Harris JR, Brown GA, Jorgensen M et al. Bone marrow-derived cells home to and regenerate retinal pigment epithelium after injury. Invest. Ophthalmol. Vis. Sci. 47, 2108–2113 (2006).
74. Klassen HJ, Ng TF, Kurimoto Y et al. Multipotent retinal progenitors express developmental markers, differentiate into retinal neurons, and preserve light-mediated behavior. Invest. Ophthalmol. Vis. Sci. 45, 4167–4173 (2004).
75. Qiu G, Seiler MJ, Mui C et al. Photoreceptor differentiation and integration of retinal progenitor cells transplanted into transgenic rats. Exp. Eye Res. 80, 515–525 (2005).
76. Limb GA, Daniels JT, Cambrey AD et al. Current prospects for adult stem cell-based therapies in ocular repair and regeneration. Curr. Eye Res. 31, 381–390 (2006).
77. Coles BL, Angenieux B, Inoue T et al. Facile isolation and the characterization of human retinal stem cells. Proc. Natl Acad. Sci. USA 101, 15772–15777 (2004).
78. MacLaren RE, Pearson RA, MacNeil A et al. Retinal repair by transplantation of photoreceptor precursors. Nature 444, 203–207 (2006).
79. Sheridan C, Williams R, Grierson I. Basement membranes and artificial substrates in cell transplantation. Graefes Arch. Clin. Exp. Ophthalmol. 242, 68–75 (2004).
80. Ratner BD, Hoffman AS, Schoen FJ, Lemons JE. Biomaterials science: a multidisciplinary endeavor. In: Biomaterials science: an introduction to materials in medicine. Ratner BD, Hoffman AS, Schoen FJ, Lemons JE (Eds). Elsevier Academic Press, CA, USA, 1–9 (2004).
81. Del Priore LV, Tezel TH, Kaplan HJ. Survival of allogeneic porcine retinal pigment epithelial sheets after subretinal transplantation. Invest. Ophthalmol. Vis. Sci. 45, 985–992 (2004).
82. Gullapalli VK, Sugino IK, Van PY, Shah S, Zarbin MA. Retinal pigment epithelium resurfacing of aged submacular human Bruch’s membrane. Trans. Am. Ophthalmol. Soc. 102, 123–137 (2004).
83. Kiilgaard JF, Wiencke AK, Scherfig E, Prause JU, La CM. Transplantation of allogenic anterior lens capsule to the subretinal space in pigs. Acta Ophthalmol. Scand. 80, 76–81 (2002).
84. Sheridan CM, Occleston NL, Hiscott P, Kon CH, Khaw PT, Grierson I. Matrix metalloproteinases: a role in the contraction of vitreo-retinal scar tissue. Am. J. Pathol. 159, 1555–1566 (2001).
85. Stanzel BV, Espana EM, Grueterich M et al. Amniotic membrane maintains the phenotype of rabbit retinal pigment epithelial cells in culture. Exp. Eye Res. 80, 103–112 (2005).
86. Tezel TH, Del Priore LV, Kaplan HJ. Reengineering of aged Bruch’s membrane to enhance retinal pigment epithelium repopulation. Invest. Ophthalmol. Vis. Sci. 45, 3337–3348 (2004).
87. Cai H, Del Priore LV. Bruch membrane aging alters the gene expression profile of human retinal pigment epithelium. Curr. Eye Res. 31, 181–189 (2006).
88. Gullapalli VK, Sugino IK, Van PY, Shah S, Zarbin MA. Impaired RPE survival on aged submacular human Bruch’s membrane. Exp. Eye Res. 80, 235–248 (2005).
89. Wang H, Ninomiya Y, Sugino IK, Zarbin MA. Retinal pigment epithelium wound healing in human Bruch’s membrane explants. Invest. Ophthalmol. Vis. Sci. 44, 2199–2210 (2003).
90. Nicolini J, Kiilgaard JF, Wiencke AK et al. The anterior lens capsule used as support material in RPE cell-transplantation. Acta Ophthalmol. Scand. 78, 527–531 (2000).
91. Turowski P, Adamson P, Sathia J et al. Basement membrane-dependent modification of phenotype and gene expression in human retinal pigment epithelial ARPE-19 cells. Invest. Ophthalmol. Vis. Sci. 45, 2786–2794 (2004).
92. Singh S, Woerly S, McLaughlin BJ. Natural and artificial substrates for retinal pigment epithelial monolayer transplantation. Biomaterials 22, 3337–3343 (2001).
93. Thumann G. Potential of pigment epithelium transplantation in the treatment of AMD. Graefes Arch. Clin. Exp. Ophthalmol. 240, 695–697 (2002).
94. Ohno-Matsui K, Ichinose S, Nakahama K et al. The effects of amniotic membrane on retinal pigment epithelial cell differentiation. Mol. Vis. 11, 1–10 (2005).
95. Thumann G, Hueber A, Dinslage S et al. Characteristics of iris and retinal pigment epithelial cells cultured on collagen type I membranes. Curr. Eye Res. 31, 241–249 (2006).
96. Hiscott P, Sheridan C, Magee RM, Grierson I. Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog. Retin. Eye Res. 18, 167–190 (1999).
97. Hsiue GH, Lai JY, Lin PK. Absorbable sandwich-like membrane for retinal-sheet transplantation. J. Biomed. Mater. Res. 61, 19–25 (2002).
98. Tezcaner A, Bugra K, Hasirci V. Retinal pigment epithelium cell culture on surface modified poly(hydroxybutyrate-co-hydroxyvalerate) thin films. Biomaterials 24, 4573–4583 (2003).
99. Lu L, Yaszemski MJ, Mikos AG. Retinal pigment epithelium engineering using synthetic biodegradable polymers. Biomaterials 22, 3345–3355 (2001).
100. Lloyd AW, Sandeman S, Faragher RG, Denyer SP. Ocular implants. In: Encyclopedia of biomaterials and biomedical engineering. Wnek GE, Bowlin GL (Eds). Marcel Dekker, NY, USA, 1098–1104 (2004).
101. Williams RL, Krishna Y, Dixon S, Haridas A, Grierson I, Sheridan C. Polyurethanes as potential substrates for sub-retinal retinal pigment epithelial cell transplantation. J. Mater. Sci. Mater. Med. 16, 1087–1092 (2005).
102. Mathew AS, Sreenivasan K, Mohanan PV, Kumary TV, Mohanty M. Polyurethane degradation in the biological milieu. Trends Biomater. Artif. Organs 19, 115–121 (2006).
103. Krishna Y, Sheridan CM, Kent DL, Grierson I, Williams RL. Polydimethylsiloxane as a substrate for retinal pigment epithelial cell growth. J. Biomed. Mater. Res. A 80, 669–678 (2007).
104. Fu RKY, Chu PKH. Plasma modification of materials. In: Encyclopedia of biomaterials and biomedical engineering. Wnek GE, Bowlin GL (Eds). Marcel Dekker, NY, USA 1–12 (2004).
105. Sieving PA, Caruso RC, Tao W et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc. Natl Acad. Sci. USA 103, 3896–3901 (2006).